The delay in approval of generic drug applications, which has been slowly declining annually, witnessed its lowest run-rate in the…
JPVL buy helps JSW Energy re-balance power assets portfolio in favour of fixed PPAs
Competition Commission has asked Sun Pharma to divest one drug and Ranbaxy six over the next six months to ensure…
The Indian Drug Manufacturers’ Association (IDMA) has written to the ministry of health and family…
Players in fragmented industry hope to grow by offering specialised tests, especially those for predicting diseases
Mylan is the world’s second-largest generic drug player in terms of revenue.
If statistics emerging from the US are any indication, Indians have a penchant for whistleblowing.
Although Adani Power is highly leveraged, it continues to shop for assets
Tata Power Renewable Energy Limited (TPREL), a subsidiary of Tata Power, is looking to add nearly 200MW of capacity annually…
Consolidation of pharma supply chains in the US is starting to hurt revenues of Indian generics players, whose sales come…
Analysts say drug maker will need another year to resolve issues
JSW Energy has put on hold its decision to buy a 500-MW thermal power plant in Bina, Rajasthan, from the…
BEST has written to the city municipal authority, asking them to increase the property tax in such a manner that…
Of the 23 observations raised by the US Food and Drug Administration during…
